|
Volumn 78, Issue 4, 2014, Pages 908-917
|
Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care--results from the Dresden NOAC registry
a a a a a a a a a a a a a a a |
Author keywords
bleeding risk; novel oral anticoagulants; switching; VKA
|
Indexed keywords
ANTICOAGULANT AGENT;
BENZIMIDAZOLE DERIVATIVE;
BETA ALANINE;
DABIGATRAN;
MORPHOLINE DERIVATIVE;
RIVAROXABAN;
THIOPHENE DERIVATIVE;
VITAMIN K GROUP;
AGED;
ANALOGS AND DERIVATIVES;
ANTAGONISTS AND INHIBITORS;
FEMALE;
HUMAN;
INTERNATIONAL NORMALIZED RATIO;
MALE;
MIDDLE AGED;
REGISTER;
VERY ELDERLY;
AGED;
AGED, 80 AND OVER;
ANTICOAGULANTS;
BENZIMIDAZOLES;
BETA-ALANINE;
DABIGATRAN;
FEMALE;
HUMANS;
INTERNATIONAL NORMALIZED RATIO;
MALE;
MIDDLE AGED;
MORPHOLINES;
REGISTRIES;
RIVAROXABAN;
THIOPHENES;
VITAMIN K;
|
EID: 84964314666
PISSN: None
EISSN: 13652125
Source Type: Journal
DOI: 10.1111/bcp.12391 Document Type: Article |
Times cited : (52)
|
References (0)
|